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Ixazomib enhances parathyroid hormone–
induced β-catenin/T-cell factor signaling by
dissociating β-catenin from the parathyroid
hormone receptor
Yanmei Yanga, Hong Leia,b, Ya-wei Qiangc, and Bin Wanga,*
a
Center for Translational Medicine, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson
University, Philadelphia, PA 19107; bCollege of Food Science and Engineering, Nanjing University of Finance and
Economics, Nanjing 210023, China; cMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock,
AR 72205

ABSTRACT The anabolic action of PTH in bone is mostly mediated by cAMP/PKA and Wntindependent activation of β-catenin/T-cell factor (TCF) signaling. β-Catenin switches the PTH
receptor (PTHR) signaling from cAMP/PKA to PLC/PKC activation by binding to the PTHR.
Ixazomib (Izb) was recently approved as the first orally administered proteasome inhibitor for
the treatment of multiple myeloma; it acts in part by inhibition of pathological bone destruction. Proteasome inhibitors were reported to stabilize β-catenin by the ubiquitin-proteasome
pathway. However, how Izb affects PTHR activation to regulate β-catenin/TCF signaling is
poorly understood. In the present study, using CRISPR/Cas9 genome-editing technology, we
show that Izb reverses β-catenin–mediated PTHR signaling switch and enhances PTH-induced
cAMP generation and cAMP response element–luciferase activity in osteoblasts. Izb increases
active forms of β-catenin and promotes β-catenin translocation, thereby dissociating β-catenin
from the PTHR at the plasma membrane. Furthermore, Izb facilitates PTH-stimulated GSK3β
phosphorylation and β-catenin phosphorylation. Thus Izb enhances PTH stimulation of βcatenin/TCF signaling via cAMP-dependent activation, and this effect is due to its separating
β-catenin from the PTHR. These findings provide evidence that Izb may be used to improve
the therapeutic efficacy of PTH for the treatment of osteoporosis and other resorptive bone
diseases.
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INTRODUCTION
Long after Bauer and colleagues discovered the anabolic effect of
parathyroid hormone (PTH) in 1929 (Bauer et al., 1929), recombinant PTH(1-34) (teriparatide) was approved as the first anabolic
agent for the treatment of osteoporosis in the United States in 2002,
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.molbiolcell.org/cgi/doi/10.1091/mbc.E17-02-0096) on May 11, 2017.
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cAMP response element-luciferase; GSK3β, glycogen synthase kinase 3β; GST,
glutathione-S-transferase; Izb, ixazomib; PKA, protein kinase A; PLC, phospholipase C; PTH, parathyroid hormone; PTHR, PTH receptor; TCF, T-cell factor.
© 2017 Yang et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available
to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported
Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).
“ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of
the Cell®” are registered trademarks of The American Society for Cell Biology.

1792 | Y. Yang et al.

and no other anabolic drugs are on the market. The optimal use of
PTH therapy in osteoporosis depends in part on our understanding
of the regulation of PTH signaling to maintain the anabolic actions
of PTH while mitigating its catabolic effects. PTH action in bone is
mediated by type 1 PTH receptor (PTHR), a member of the G protein–coupled receptor superfamily. Stimulation of PTHR by PTH on
osteoblasts leads to activation of Gαs and Gαq, with consequent
induction of cAMP/protein kinase A (PKA) and phospholipase C
(PLC)/PKC signaling pathways, which results in both osteoblast formation and osteoclast resorption (Qin et al., 2004; Cheloha et al.,
2015). Whereas anabolic PTH effects in bone are mediated mostly
through the cAMP/PKA signaling pathway, PLC/PKC signaling has
been shown to be inhibitory to the osteoanabolic actions of PTH
(Ogata et al., 2011). Wnt/β-catenin signaling controls bone formation and homeostasis by increasing osteoblast differentiation and
inhibiting osteoclastogenesis (Gaur et al., 2005; Glass et al., 2005;

Supplemental Material can be found at:
http://www.molbiolcell.org/content/suppl/2017/05/08/mbc.E17-02-0096v1.DC1
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Liu et al., 2015). Our data and those from other groups show that
β-catenin interacts with the PTHR and switches the PTHR signaling
from Gαs/cAMP to Gαq/PLC activation (Yano et al., 2013; Yang and
Wang, 2015). There is cross-talk between PTHR and frizzled receptor
to regulate PTH action in bone (Wan et al., 2008; Romero et al.,
2010; Revollo et al., 2015). The low-density lipoprotein receptor–
related protein 6 (LRP6), one of frizzled’s coreceptors, is a key element of the PTH signaling for regulating osteoblast activity (Wan
et al., 2008; Revollo et al., 2015). PTHR directly interacts with
Dishevelled to regulate β-catenin signaling and osteoclast differentiation (Romero et al., 2010). PTH facilitates canonical Wnt signaling
via inactivation of glycogen synthase kinase 3β (GSK3β) in osteoblasts to inhibit β-catenin sequestration (Suzuki et al., 2008). These
findings highlight the role of β-catenin/T-cell factor (TCF) signaling
in anabolic action of PTH in bone. It is unclear how β-catenin directly
contributes to the osteoanabolic action of PTH.
β-Catenin is a multifunctional protein and does not contain a
transmembrane domain (Nelson and Nusse, 2004; Stepniak et al.,
2009; Marie et al., 2014). Cadherins, which have a single-pass transmembrane domain, bind to β-catenin through their carboxyl-terminal domain at the cytoplasmic tail. Thus β-catenin serves as a link
between cadherins and the actin cytoskeleton to mediate the role of
cadherins in cell adhesion (Nelson and Nusse, 2004; Stepniak et al.,
2009; Marie et al., 2014). In addition, β-catenin also binds to numerous other proteins in a cadherin-independent manner (Bienz and
Clevers, 2003; Yano et al., 2013; Yang and Wang, 2015). In bone,
N-cadherin associates with β-catenin at the cell membrane to regulate osteoblastogenesis by limiting Wnt signaling. Revollo et al.
(2015) reported that N-cadherin modulated LRP6-PTHR interaction,
restrained the intensity of PTH-induced β-catenin signaling, and reduced bone formation in response to intermittent PTH administration. Moreover, N-cadherin restrains PTH’s repressive effects on
sclerostin/SOST by regulating LRP6-PTHR interaction (Yang et al.,
2016). The interaction of N-cadherin with β-catenin causes increased
cadherin abundance on the cell surface and results in β-catenin sequestration at the plasma membrane (Stepniak et al., 2009; Marie
et al., 2014). The outcome reduces β-catenin nuclear translocation
and decreases TCF/lymphoid enhancer factor–dependent transcriptional activity. Accordingly, blockade of β-catenin degradation may
enhance PTH stimulation of β-catenin/TCF signaling.
The ubiquitin-proteasome pathway plays an important role in
regulating and controlling bone metabolism (Murray et al., 1998;
Garrett et al., 2003; Yang et al., 2015). The first-generation proteasome inhibitor bortezomib has been used as an effective therapy for
the treatment of multiple myeloma, a disease characterized by an
increase in the activity of osteoclasts and a decrease in the function
of osteoblasts adjacent to tumor cells in the bone marrow (Pennisi
et al., 2009). Carfilzomib, a next-generation selective proteasome
inhibitor, exhibits potent antimyeloma efficacy compared with bortezomib (Herndon et al., 2013; Berenson et al., 2014). We previous
reported that carfilzomib suppressed PTH stimulation of osteoclast
differentiation and bone-resorptive activity to mitigate the catabolic
effects of PTH (Yang et al., 2015). A significant limitation of treatment
with bortezomib and carfilzomib is that both drugs are administered
intravenously or subcutaneously, which is inconvenient for patients
and increases treatment cost. Ixazomib (Izb) is a small-molecule proteasome inhibitor that overcomes these limitations. In November
2015, Izb became the first orally administered proteasome inhibitor
approved in the United States as an effective therapy for multiple
myeloma. This effect is mediated in part through inhibition of pathologic bone destruction (Kupperman et al., 2010; Garcia-Gomez et al.,
2014; Muz et al., 2016). Proteasome inhibitors such as bortezomib
Volume 28 July 1, 2017

and carfilzomib directly stabilize β-catenin protein and increase free
cytosolic β-catenin and β-catenin nuclear translocation (Qiang et al.,
2009; Hu et al., 2013). However, how proteasome inhibition regulates the complex interplay between PTHR and β-catenin to in turn
regulate β-catenin/TCF signaling has not been elucidated.
In the present study, we show that Izb reverses the β-catenin–
mediated PTHR signaling switch by enhancing PTH-induced cAMP
formation and cAMP response element-luciferase (CRE-luc) reporter
gene activity and reducing PTH-stimulated intracellular calcium mobilization in osteoblasts. Izb enhances PTH-induced β-catenin/TCF
signaling by separating β-catenin from the PTHR and promoting
β-catenin translocation.

RESULTS
Knockout of β-catenin increases PTH-induced cAMP
formation and reduces intracellular calcium in osteoblasts
Recent findings show that β-catenin switches the PTHR signaling by
binding to the intracellular carboxyl-terminal region of the PTHR in
both chondrocytes and HEK293 cells (Yano et al., 2013; Yang and
Wang, 2015). In an initial set of experiments, we examined whether
β-catenin also switched the PTHR signaling in osteoblasts. Saos2
osteoblastic cells endogenously express both β-catenin and the
PTHR (Wang et al., 2009). These cells were transfected with a clustered regularly interspaced short palindromic repeats (CRISPR) construct or CRISPR control plasmid. After 48 h of transfection, the cells
were transferred into a 96-well plate with one cell per well by a serial
dilution. Two single colonies were identified for knockout of βcatenin expression in Saos2 cells (hereafter referred to as Saos2-βCat-KO-3 and Saos2-β-Cat-KO-10 cells; Figure 1A), whereas no
β-catenin expression was reduced in cells transfected with control
plasmid (Saos2-β-Cat-Ctr; Supplemental Figure S1).
To assess the effect of β-catenin on PTH-induced Gαs/cAMP signaling, we conducted PTH stimulation of cAMP generation in Saos2β-Cat-KO-3 cells (β-Cat KO) and their control cells (Saos2-β-CatCtr-1, WT Ctr). Knockout of β-catenin significantly increased
PTH(1-34) (hereafter referred to as PTH) stimulation of cAMP formation (Figure 1B). To evaluate PTHR-mediated Gαq/PLC signaling,
we measured intracellular calcium mobilization ([Ca2+]i), an index of
PLC activity, in Saos2-β-Cat-KO-3 cells and Saos2-β-Cat-Ctr-1 cells
loaded with the calcium-sensitive dye Fluo-4 AM. Knockout of βcatenin markedly inhibited PTH-induced [Ca2+]i (Figure 1C). Similar
results also occurred in Saos2-β-Cat-KO-10 and Saos2-β-Cat-Ctr-2
cells (unpublished data). Collectively these data clearly demonstrate
that knockout of β-catenin reverses the PTHR signaling switch to
increase Gαs/cAMP signaling and reduce Gαq/PLC activation,
which favors the anabolic PTH action in bone.

Izb enhances PTH-induced cAMP formation in a
time- and concentration-dependent manner
We previously reported that proteasome inhibitors stabilized βcatenin by the ubiquitin-proteasome pathway (Qiang et al., 2009;
Hu et al., 2013). Because β-catenin switches PTHR signaling, we
next determined whether Izb regulated PTHR activation. Izb alone
was not able to stimulate cAMP formation (Supplemental Figure
S2). However, pretreatment of Izb enhanced PTH stimulation of
cAMP formation in Saos2 cells, which exhibited time and concentration dependence. Maximal stimulation by Izb was achieved at 3 h
(Figure 2A), but prolonged Izb treatment tended to reduce its effect
on PTH-induced cAMP formation. At the 3 h, Izb elicited a concentration-dependent increase in PTH-induced cAMP formation over
the range 12.5–100 nM (Figure 2B), but higher concentrations of Izb
also decreased its effect on PTH stimulation of cAMP production.
Ixazomib regulates PTH signaling
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with Izb, carfilzomib, or vehicle for the first
3 h, followed by an additional 5 h of culture
in Izb- or carfilzomib-free medium. Izb and
carfilzomib exhibited increases in the free
cytosolic β-catenin level in a concentrationdependent manner (Figure 3A). In addition,
Izb increased nuclear β-catenin expression
(Figure 3B). An independent experiment performed by confocal microscopy showed that
Izb induced β-catenin translocation in Saos2
cells, as shown by its accumulation in cytosol
and nucleus (Supplemental Figure S5).
The PTHR is a seven-transmembrane domain protein, whereas β-catenin does not
contain any transmembrane domain in its
structure. Because Izb increases active forms
of β-catenin and promotes β-catenin translocation, we asked whether Izb was able to
separate β-catenin from the PTHR at the
plasma membrane. Saos2 cells were transfected with pCDNA3.1 vector, hemagglutinin (HA)-PTHR, and/or Flag–β-catenin as inFIGURE 1: Knockout of β-catenin switches the PTHR signaling from Gαq/PLC to Gαs/cAMP
dicated. After 48 h of transfection, the cells
activation. Saos2 cells in a six-well plate were transfected with CRISPR construct or control
were treated with vehicle or Izb (100 nM) for
plasmid. After 48 h, the cells, which expressed only OFP reporter as visualized using an Evos
3 h, followed by an additional 5 h of culture
machine, were transferred into a 96-well plate with one cell per well. (A) After ∼3 wk, two single
in Izb-free medium. The membrane proteins
colonies (Saos2-β-Cat-KO-3 and Saos2-β-Cat-KO-10 cells) were identified for knockout of
were isolated, and the interaction of Flag-ββ-catenin expression in Saos2 cells by Western blotting. Immunoblotting was performed with
catenin with HA-PTHR was performed by imprimary antibodies of mouse monoclonal β-catenin (β-Cat) antibody plus rabbit polyclonal actin
munoprecipitation assay. The result in Figure
antibody and then with secondary antibodies (goat anti-mouse antibody [red] plus goat
3C show that treatment with Izb reduced the
anti-rabbit antibody [green]). Actin was used for loading control. (B, C) Saos2-β-Cat-KO-3 cells
(β-Cat KO) and control Saos2-β-Cat-Ctr-1 cells (WT Ctr) were set up in a 24- or 96-well plate.
interaction of β-catenin with the PTHR at the
After 24 h of culture, cells were serum starved overnight. PTH (100 nM) stimulation of
plasma membrane, further confirming that
intracellular cAMP accumulation (B) or PTH (1 µM) induction of intracellular calcium (C) was
Izb promotes β-catenin translocation to
measured as described in Materials and Methods. Data are summarized as mean ± SE of
cytosol and nucleus. As a complementary
triplicate measurements. n = 4. ap < 0.05, bp < 0.01, compared with WT Ctr cells treated with
experiment, Saos2 cells were transiently
c
d
e
f
vehicle; p < 0.05, p < 0.01, compared with WT Ctr cells treated with PTH; p < 0.05, p < 0.01,
transfected with green fluorescent protein
compared with β-Cat KO cells treated with vehicle.
(GFP)–PTHR. After 48 h of transfection, the
cells were treated with vehicle or Izb as before. There was a colocalization of β-catenin with the PTHR at the
Similar to other proteasome inhibitors (Qiang et al., 2009; Hu et al.,
plasma membrane in the absence of Izb, whereas Izb reduced this
2013), Izb but not PTH caused slight cytotoxicity when the cells were
colocalization (Figure 3D). Collectively Izb enhanced PTH-induced
treated with it for a prolonged time or at higher concentrations
cAMP generation due to the separation of β-catenin from the PTHR.
(Supplemental Figure S3, A–C). To reduce the cytotoxicity of Izb, we
pretreated Saos2 cells with Izb or vehicle for the first 3 h, followed
Izb regulation of the PTHR signaling is β-catenin dependent
by an additional 5 h of culture in Izb-free medium, which mimics the
To test whether the specificity of Izb effect on PTH-induced cAMP
pulse treatment used in the clinic and avoids unselective cytotoxicity
of proteasome inhibition (Boissy et al., 2008). As expected, this regiproduction is due to separation of β-catenin from the PTHR, we
men of Izb not only enhanced PTH stimulation of cAMP formation,
used both wild-type and β-catenin–knockout Saos2 cells. Indeed,
Izb failed to enhance PTH-induced cAMP formation and reduce inbut it also reduced its cytotoxicity (Figure 2, C and D). To verify these
results, we also found that Izb enhanced PTH-induced cAMP gentracellular calcium mobilization in β-catenin–knockout cells comeration in mouse primary osteoblasts (Supplemental Figure S4).
pared with that of wild-type Saos2 control cells (Figure 4).

Izb promotes PTH stimulation of cAMP formation by
facilitating the dissociation of β-catenin from the PTHR

There are different cellular pools of β-catenin in the plasma membrane, cytosol, and nucleus. In most cells, the majority of β-catenin is
located at the plasma membrane in a complex with cadherins or
other proteins (Stepniak et al., 2009; Marie et al., 2014). Previous findings reported that both bortezomib and carfilzomib increased free
and active forms of β-catenin in Saos2 cells (Qiang et al., 2009; Hu
et al., 2013). We used an affinity-based E-cadherin–glutathione-Stransferase (GST) pull-down assay to separate the free β-catenin from
the pool of membrane-bound β-catenin. Saos2 cells were treated
1794 | Y. Yang et al.

Izb promotes PTH-induced CRE-luc activity and cAMP
response element–binding phosphorylation
We next determined the effect of Izb on cAMP/PKA downstream
signaling in osteoblasts. The active catalytic subunit of PKA stimulates CRE-luc activity (Castellone et al., 2005). Wild-type Saos2 control cells or Saos2-β-Cat-KO cells were infected with lentiviral particles containing CRE-luc reporter gene. The cells were pretreated
with Izb (100 nM for 1 h) before PTH (100 nM) was added to the
culture for another 2 h. The CRE-luc activity was then measured. As
shown in Figure 5A, Izb itself was not able to stimulate CRE-luc activity in wild-type control or β-catenin–knockout cells. However,
Molecular Biology of the Cell

cells, and this change was not affected by Izb
in these cells (Figure 5C), further confirming
that effects of Izb on PTHR downstream
events are β-catenin dependent and mediated by the cAMP/PKA signaling pathway.

Izb enhances PTH stimulation of
GSK3β phosphorylation at Ser-9 and
β-catenin phosphorylation at Ser-675

FIGURE 2: Izb enhances PTH-induced cAMP formation in a time- and concentration-dependent
manner. (A) Time course of Izb on PTH-stimulated cAMP formation. Saos2 cells were seeded onto
a six-well plate. After 90% confluence, the cells were transfected with Glosensor cAMP reporter
plasmid (pGS-22F) using Lipofectamine 2000. At 36 h after transfection, cells were transferred
into a 96-well plate and cultured for 14 h. The cells were serum starved overnight and then
treated with vehicle or Izb (100 nM) for the indicated times, and PTH-induced cAMP formation
was measured. The peak response time for cAMP formation is 14 min. (B) Concentration response
of Izb on PTH-stimulated cAMP formation. At 3 h, Izb (12.5–100 nM) concentration dependently
increased PTH stimulation of cAMP formation. (C) Pulse treatment of Izb increases of PTHstimulated cAMP formation. Saos2 cells were treated with Izb (100 nM) for 8 h or for the first 3 h
followed by an additional 5 h of culture in Izb-free medium in Saos2 cells. (D) Pulse treatment of
Izb reduces cytotoxicity. Saos2 cells were treated with Izb (100 nM) for 8 h or for the first 3 h
followed by an additional 5 h of culture in Izb-free medium in the presence of PTH (100 nM) in
Saos2 cells. Cytotoxicity was assessed by MTT assay as described in Materials and Methods. Data
are summarized as mean ± SE of triplicate measurements. n = 3. ap < 0.05, bp < 0.01, compared
with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with PTH.

knockout of β-catenin significantly increased PTH-induced CRE-luc
activity. Izb failed to enhance PTH stimulation of CRE-luc activity in
β-catenin–knockout cells compared with wild-type control cells.
cAMP response element–binding (CREB) protein signaling plays a
key role in regulating osteoblast activity and bone formation (Long
et al., 2001). PTH can induce phosphorylation of CREB through the
cAMP/PKA signaling pathway (Pearman et al., 1996; Revollo et al.,
2015). Saos2 wild-type cells were pretreated with Izb (100 nM for 2 h)
before PTH (100 nM) was added to the culture for another 1 h. PTH
markedly induced CREB phosphorylation (Figure 5B). Izb by itself had
no effect on phosphorylation of CREB but facilitated PTH stimulation
of CREB phosphorylation. Total CREB abundance was unaffected in
each group. PKA inhibitor H89 or PKC inhibitor bisindolylmaleimide I
(Bis I) alone had no effect on CREB phosphorylation (Supplemental
Figure S6). However, H89 but not Bis I blocked Izb enhancement of
PTH-induced CREB phosphorylation (Figure 5B). In addition, PTH significantly stimulated CREB phosphorylation in β-catenin–knockout
Volume 28 July 1, 2017

The stability of β-catenin is regulated by a
multiprotein complex, which includes adenomatous polyposis coli, GSK3β, and axin.
PKA phosphorylates GSK3β at the amino
acid Ser-9, which inhibits its kinase activity
and then inactivates the β-catenin destruction complex (Castellone et al., 2005; Suzuki
et al., 2008). PTH induces β-catenin/TCF signaling via inactivation of GSK3β in osteoblasts (Suzuki et al., 2008). Saos2 cells were
pretreated with Izb (100 nM) for 2.5 h, and
PTH (100 nM) was then added for another 30
min. GSK3β functions upstream of β-catenin
activation. As expected, Izb by itself has no
effect on GSK3β phosphorylation at Ser-9
(Figure 6A). PTH treatment increased GSK3β
phosphorylation, and Izb further enhanced
PTH stimulation of GSK3β phosphorylation.
PKA-phosphorylated β-catenin at Ser675 increases β-catenin accumulation in the
cytosol, thereby promoting β-catenin downstream signaling (Taurin et al., 2006; Revollo
et al., 2015). We hypothesized that Izb enhanced PTH-induced phosphorylated βcatenin at this site. To test this idea, we pretreated Saos2 cells with Izb for 1 h. Then we
added 100 nM PTH to culture for another
2 h. The data in Figure 6B show that PTH
stimulated β-catenin phosphorylation at Ser675. Izb but not PTH slightly increased total
β-catenin abundance. However, Izb and
PTH synergistically increased β-catenin (Ser675) phosphorylation, although Izb on its
own had no notable effect on the phosphorylation of β-catenin.

Izb promotes PTH-induced β-catenin/TCF signaling
in osteoblasts
PTH-facilitated β-catenin/TCF signaling is cAMP/PKA dependent
(Kulkarni et al., 2005; Suzuki et al., 2008). Our data show that Izb enhanced PTH-induced cAMP formation and promoted PTH stimulation of GSK3β and β-catenin phosphorylation. These findings suggest
an additional mechanism by which Izb enhances PTH-induced βcatenin/TCF signaling in osteoblasts. To test this idea, we transfected
Saos2 cells with TOPflash or FOPflash plasmid. The cells were treated
with Izb for the first 3 h, followed by an additional 5 h culture in Izbfree medium in the presence or absence of PTH for 8 h. After treatment, the TOPflash and FOPflash reporter activities were measured.
Both bortezomib and carfilzomib induce osteoblast differentiation via
Wnt-independent induction of β-catenin translocation and activation
of β-catenin/TCF signaling (Qiang et al., 2009; Hu et al., 2013). As
we predicted, Izb by itself stimulated nuclear β-catenin expression
and β-catenin/TCF signaling (Figure 7, A and B). Izb and PTH
Ixazomib regulates PTH signaling
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synergistically increased nuclear β-catenin
levels and β-catenin/TCF activation. Similar
results were also identified in mouse osteoblasts (Supplemental Figure S7). PKA inhibitor H89 but not PKC inhibitor Bis I inhibited
PTH-stimulated TCF reporter activity (Figure
7B), confirming that PTH-stimulated βcatenin/TCF signaling is cAMP/PKA dependent. However, H89 only partially reversed
the effect of Izb on PTH stimulation of βcatenin/TCF activation. Furthermore, H89
failed to affect Izb increase of free cytosolic
β-catenin level, nuclear β-catenin expression
(Supplemental Figure S8, A and B), and βcatenin/TCF signaling (Supplemental Figure
S8D). H89 also had no effect on β-catenin
phosphorylation at Ser-675 in the presence
of Izb (Supplemental Figure S8C). These
data clearly demonstrate that the effect of
Izb alone on β-catenin translocation and βcatenin/TCF signaling is not related to a
cAMP/PKA pathway. Together the results
show that, in addition to being capable of
promoting β-catenin translocation, Izb enhances PTH stimulation of β-catenin/TCF
signaling via an increase in cAMP-dependent signaling.

DISCUSSION
Although PTHR signaling pathways are being studied in increasing detail, the regulation of PTHR functions has not been fully
elucidated. The anabolic PTH effects on
bone are mostly mediated by the Gαs/
cAMP signaling pathway, whereas Gαq/PLC
activation may antagonize these osteoanabolic actions (Datta and Abou-Samra, 2009;

FIGURE 3: Izb facilitates the separation of β-catenin from PTHR. (A) Izb increases free β-catenin
protein levels. Left, top, Saos2 cells treated with vehicle, Izb (25, 100 nM), or carfilzomib (Cfz,
12.5, 50 nM) for the first 3 h followed by an additional 5 h of culture in Izb- or Cfz-free medium.
GST–E-cadherin was bound to free β-Cat, and the complexes were purified using GST beads.
Immunoblotting was then performed with primary antibodies of mouse monoclonal β-Cat
antibody plus rabbit polyclonal actin antibody and then with secondary antibodies (goat
anti-mouse antibody and goat anti-rabbit antibody). Lack of actin expression suggests that the
beads were washed completely. Left, bottom, immunoblotting conducted with total lysates with
the same primary antibodies and secondary antibodies. Right, quantified free β-catenin levels in
three independent experiments presented as mean ± SE. ap < 0.05, bp < 0.01, compared with
cells treated with vehicle. (B) Izb increases nuclear β-catenin expression. Saos2 cells were treated
1796 | Y. Yang et al.

with vehicle or Izb as in A. Left, nuclear
proteins were prepared and β-catenin
expression analyzed by immunoblotting.
Right, quantified nuclear β-catenin levels in
three independent experiments presented as
mean ± SE. ap < 0.05, bp < 0.01, compared
with cells treated with vehicle. (C) Saos2 cells
were transfected with pCDNA3.1 vector,
HA-PTHR, and/or Flag-β-Cat as indicated.
After 48 h of transfection, the cells were
treated with vehicle or Izb (100 nM) as before.
Left, the plasma membrane proteins were
isolated, and the interaction of Flag-β-Cat
with HA-PTHR measured. Right, coIP of
β-catenin with PTHR in three independent
experiments normalized to HA-PTHR band.
b
p < 0.01, compared with cells treated with
vehicle. (D) Saos2 cells were transfected with
GFP-PTHR. After 48 h, the cells were treated
with vehicle or Izb (100 nM) as before. The
cells were fixed, stained, and visualized for
colocalization of PTHR with β-catenin by
confocal microscopy. Representative of three
independent experiments performed with
similar results. Scale bar, 10 µm.
Molecular Biology of the Cell

important question of whether the intervention of β-catenin interaction with PTHR in
osteoblasts has a similar effect to alter PTHinduced PTHR signaling. Proteasome inhibitors such as bortezomib and carfilzomib,
which have been used to treat multiple myeloma patients, were shown to directly stabilize β-catenin protein and increase βcatenin nuclear translocation (Qiang et al.,
2009; Hu et al., 2013). In the present study,
we chose Izb, the first orally administered
proteasome inhibitor for the treatment of
multiple myeloma, because it has the potential to treat resorptive bone diseases
such as osteoporosis. We found that Izb inFIGURE 4: Izb blocks β-catenin–mediated PTHR signaling switch. Saos2-β-Cat-KO-3 cells
creased active β-catenin expression and
(β-Cat KO) and their control cells (Saos2-β-Cat-Ctr-1, WT Ctr) were seeded onto a 24- or 96-well
translocation (Figure 3 and Supplemental
plate. After confluence, the cells were serum starved overnight and then pretreated with Izb
(100 nM) for 3 h. PTH stimulation of cAMP formation (A) and intracellular calcium (B) were
Figure S5). Most importantly, we found, usmeasured. Data are summarized as mean ± SE of triplicate measurements. n = 3. ap < 0.05,
ing coimmunoprecipitation (coIP) and conb
p < 0.01, compared with WT Ctr cells treated with vehicle; cp < 0.05, dp < 0.01, compared with
focal microscopy, that Izb was able to sepaWT Ctr cells treated with PTH; ep < 0.05, fp < 0.01, compared with WT Ctr cells treated with Izb; rate β-catenin from the PTHR at the cell
g
p < 0.05, hp < 0.01, compared with β-Cat KO cells treated with vehicle; ip < 0.05, jp < 0.01,
membrane. Pretreatment of Izb increased
compared with β-Cat KO cells treated with PTH; kp < 0.05, lp < 0.01, compared with β-Cat KO
PTH-stimulated cAMP production and recells treated with Izb.
duced PTH-induced PLC activity (Figure 4
and Supplemental Figure S4), demonstrating that Izb can inhibit the PTHR signaling switch to increase cAMP
Ogata et al., 2011). Additional anabolic signaling by PTH action information in osteoblasts by promoting the dissociation of β-catenin
volves the canonical β-catenin pathway, which is independent of
from the PTHR. To the best of our knowledge, this is the first report
Wnt. Therefore manipulating PTHR signaling by shifting Gαq/PLC
showing how a proteasome inhibitor regulates PTHR signaling by
to Gαs/cAMP activation and increasing β-catenin/TCF signaling
dissociating β-catenin from the PTHR.
represents a means of maintaining the anabolic actions of PTH.
It is established that PTH-induced β-catenin/TCF signaling is
Sequences located at the carboxyl terminus of PTHR control its
cAMP/PKA dependent (Kulkarni et al., 2005; Suzuki et al., 2008).
signaling (Datta and Abou-Samra, 2009; Romero et al., 2011). PTHR
CRE-luc activity and CREB phosphorylation are downstream events
has a PSD-95/Discs large/ZO-1 (PDZ) motif located in the last four
that depend on cAMP/PKA activation. We demonstrated that Izb by
amino acids, which interact with NHERF1 and NHERF2 (Romero
itself had no effect on CRE-luc activity and CREB phosphorylation
et al., 2011; Vilardaga et al., 2011). As originally described by Mahon
but enhanced PTH stimulation of CRE-luc activity and phosphorylaet al. (2002), NHERF2, a NHERF1 homologue, markedly inhibits adtion of CREB (Figure 5). Furthermore, Izb and PTH synergistically
enylyl cyclase by stimulating inhibitory Gαi proteins in PS120 cells
increased GSK3β phosphorylation at Ser-9 and phosphorylated βtransfected with the PTHR. In contrast, no differences of PTH-stimucatenin at Ser-675 (Figure 6), the outcome of which results in βlated cAMP formation were noted between wild-type and NHERF1catenin translocation to the nucleus. It is known that PTH-induced
null proximal tubule cells (Cunningham et al., 2005) in the presence
β-catenin/TCF activation takes >6 h. Similar to other proteasome
or absence of NHERF1. In ROS17/2.8 cells or primary osteoblasts,
inhibitors, Izb treatment in cells for >3 h has some cytotoxicity
NHERF1 increases PTH-stimulated cAMP accumulation (Wheeler
(Boissy et al., 2008). To maintain Izb biological activity and avoid its
et al., 2008; Wang et al., 2013). Moreover, truncation of the cartoxicity, Saos2 cells received Izb for the first 3 h, followed by an adboxyl-terminal region of the PTHR that lacks determinants for stable
ditional 5 h of culture in Izb-free medium. Our findings show that Izb
β-arrestin association (PTHR-480stop) enhances PTH stimulation of
enhanced PTH-induced β-catenin/TCF signaling without inducing
adenylyl cyclase but not PLC (Iida-Klein et al., 1995; Wang et al.,
cytotoxicity (Figures 2 and 7). Therefore our work reveals a novel
2007). In contrast to the aforementioned regulatory proteins, βrole for Izb in regulating PTH-induced β-catenin/TCF signaling via
catenin specifically binds to the intracellular carboxyl-terminal rethe cAMP/PKA-dependent pathway.
gion of the PTHR and switches the PTHR signaling from Gαs/cAMP
The increase of cytosolic and nuclear β-catenin by proteasome
to Gαq/PLC activation in chondrocytes and HEK293 cells (Yano
inhibition is via its specific inhibition of β-catenin degradation but
et al., 2013; Yang and Wang, 2015). As an initial step, we deterindependent of Wnt ligands and not related to GSK3β phosphorymined whether this signaling switch by β-catenin also occurred in
lation (Qiang et al., 2009). In the present study, we demonstrated
osteoblasts. To that end, we generated a β-catenin–knockout cell
that Izb by itself does not affect GSK3β phosphorylation at Ser-9
line in osteoblasts using CRISPR/Cas9 genome-editing technology.
and β-catenin phosphorylation at Ser-675. Thus the underlying
Our data showed that knockout of β-catenin (i.e., zero expression of
mechanisms by which Izb induces β-catenin/TCF signaling are not
β-catenin) significantly increased PTH-induced cAMP formation,
fully understood. Proteasome inhibition can stabilize numerous
whereas PTH-stimulated PLC activity was markedly reduced in these
proteins. PTHR directly interacts with Dishevelled to regulate βknockout cells compared with cells transfected with CRISPR/Cas9
catenin signaling (Romero et al., 2010). Zhou et al. (2016) recently
control plasmid (Figure 1). These data are consistent with a previous
reported that ubiquitin-specific protease 4 strongly inhibited
study, using small interfering RNA, demonstrating that knockdown
Wnt/β-catenin signaling by removing lysine-63 linked polyubiquitin
of β-catenin (i.e., reduction of β-catenin expression) inhibited the
chain from Dishevelled and antagonized osteoblast differentiation
PTHR signaling switch (Yano et al., 2013). These findings raised an
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FIGURE 5: Izb enhances PTH-induced CRE-luc activity and CREB phosphorylation. (A) Knockout
of β-catenin increases PTH-induced CRE-luc activity. Saos2-β-Cat-KO-3 cells (β-Cat KO) and their
control cells (Saos2-β-Cat-Ctr-1, WT Ctr) were seeded onto a 24-well plate. After cells reached
80% confluence, the cells were infected with lentiviral particles of CRE-luc reporter and cultured
for 48 h. The cells were serum starved overnight and then pretreated with Izb (100 nM for 1 h)
before PTH (100 nM) was added to the culture for another 2 h. PTH induction of CRE-luc activity
in each group was measured as described in Material and Methods. Data are summarized as
mean ± SE of triplicate measurements. n = 3. ap < 0.05, bp < 0.01, compared with WT Ctr cells
treated with vehicle; cp < 0.05, dp < 0.01, compared with WT Ctr cells treated with PTH;
e
p < 0.05, fp < 0.01, compared with WT Ctr cells treated with Izb; gp < 0.05, hp < 0.01,
compared with β-Cat KO cells treated with vehicle; ip < 0.05, jp < 0.01, compared with β-Cat KO
cells treated with PTH; kp < 0.05, lp < 0.01, compared with β-Cat KO cells treated with Izb.
(B) Izb enhancement of PTH-induced CREB phosphorylation is cAMP/PKA dependent. Saos2-βCat-Ctr-1 cells (WT Ctr) were pretreated with Izb (100 nM for 2 h) before PTH (100 nM) was
added to the culture for another 1 h in the presence or absence of PKA inhibitor H89 (10 µM) or
PKC inhibitor Bis I (10 µM) for 1 h and 15 min. Left, PTH-induced CREB phosphorylation and
total CREB expression (loading control). Right, quantified CREB phosphorylation and total CREB
expression in four independent experiments presented as mean ± SE. ap < 0.05, bp < 0.01,
compared with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with
PTH; ep < 0.05, fp < 0.01, compared with cells treated with Izb; gp < 0.05, hp < 0.01, compared
with cells treated with PTH plus Izb. (C) Izb fails to affect PTH stimulation of CREB
1798 | Y. Yang et al.

and mineralization through Dishevelled
degradation. Therefore we do not exclude
the possibility that Izb enhancement of PTH
stimulation of β-catenin/TCF signaling may
be related to its inhibition of Dishevelled
degradation. In addition, PTHR activation,
desensitization, endocytosis, and recycling
proceed in a cyclical manner. We previously
reported that PTHR recycling was complete
by 2 h after stimulation with PTH(1-34), a
biologically active peptide fragment, suggesting the PTHR trafficking is different
from that of β-catenin. However, PTH(7-34),
which does not activate the PTHR but promotes receptor internalization, down-regulates the PTHR by a ubiquitin-sensitive
pathway (Sneddon et al., 2003; Alonso
et al., 2011). Continuous and high-dose
PTH(1-34) causes bone resorption and hypercalcemia (Qin et al., 2004; Cheloha
et al., 2015). Future investigations will need
to assess the roles of proteasome inhibition
on prolonged PTH treatment in induction
of both cAMP formation and β-catenin/TCF
signaling in bone cells.
On the basis of the present findings and
generally accepted roles of proteasome inhibitor and β-catenin/TCF, we propose a
model (Figure 8) for the effect of Izb on regulation of PTHR signaling cascade in bone.
According to this notion, Izb regulates PTHR
signaling by dissociating β-catenin from the
PTHR to enhance PTH-induced β-catenin/
TCF activity. Such an effect is cAMP/PKA dependent. Izb has been applied for the treatment of both the tumor burden and bone
loss associated with multiple myeloma.
Whereas our previous study emphasized
that proteasome inhibition mitigated the
catabolic effect of PTH on bone by suppressing PTH-induced osteoclast differentiation and bone-resorptive activity (Yang
et al., 2015), the present study demonstrates that Izb can regulate the PTHR signaling in osteoblasts, which favors anabolic
PTH action in bone. These findings warrant
further investigation of this combination of
PTH and Izb on osteoblast differentiation

phosphorylation in β-catenin–knockout cells.
Saos2-β-Cat-KO-3 cells (β-Cat KO) cells were
pretreated with Izb (100 nM for 2 h) before
PTH (100 nM) was added to the culture for
another 1 h. Left, PTH stimulation of CREB
phosphorylation. Right, quantified CREB
phosphorylation and total CREB expression
in three independent experiments presented
as mean ± SE. ap < 0.05, bp < 0.01, compared
with cells treated with vehicle; cp < 0.05,
d
p < 0.01, compared with cells treated with
PTH; ep < 0.05, fp < 0.01, compared with
cells treated with Izb.
Molecular Biology of the Cell

(Carlsbad, CA). Glosensor cAMP reporter
plasmid (pGS-22F) was purchased from Promega (Madison, WI). Protease inhibitor
cocktail Set I, H89, and Bis I were from
Calbiochem (San Diego, CA). The Cyclic
AMP Direct EIA Kit was purchased from
Arbor Assays (Ann Arbor, MI). Ionomycin
was from EMD Millipore (Billerica, MA). All
other reagents were from Sigma-Aldrich (St.
Louis, MO).

Cell culture
Saos2 cells, a human osteoblast–like cell line,
were purchased from the American Type
Culture Collection (ATCC; Manassas, VA)
and cultured in DMEM/F-12 with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and
100 μg/ml streptomycin. MC4 osteoblastic
cells (subclone 4 of MCT3-E1; ATCC) were
cultured in α-MEM with 10% FBS in the presence of 50 μg/ml ascorbic acid for 5 d and
then used in the experiments. All cells were
maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air.

Primary osteoblast culture
All of the experiments using mice for generation of primary osteoblasts were performed
according to the protocol approved by the
FIGURE 6: Izb facilitates PTH stimulation of GSK3β and β-catenin phosphorylation. (A) Saos2
cells were seeded onto a six-well plate. After confluence, the cells were serum starved overnight Animal Care and Use Committee of Thomas
Jefferson University. Generation of primary
and then pretreated with Izb (100 nM) for 2.5 h, and PTH (100 nM) was then added to the
culture for another 30 min. Left, PTH-induced GSK3β phosphorylation and total GSK3β
osteoblast cultures was described previously
expression. Right, quantified GSK3β phosphorylation at Ser-9 and total GSK3β expression in
(Yang et al., 2015). Briefly, calvariae were refour independent experiments presented as mean ± SE. (B) Saos2 cells were grown in a six-well
moved from 2- to 3-d-old C57BL/6 mice and
plate and cultured as before. The cells were pretreated with Izb (100 nM) for 1 h, and PTH
digested with 1 mg/ml collagenase type II
(100 nM) was then added to the culture for another 2 h. Left, PTH-induced β-catenin
and 0.25% trypsin-EDTA. Cells released
phosphorylation at Ser-675 and total β-catenin expression. Actin was used for loading control.
from the second and third digestions were
Right, quantified β-catenin phosphorylation and total β-catenin expression in four independent
grown in α-MEM supplemented with 10%
a
b
experiments presented as mean ± SE. p < 0.05, p < 0.01, compared with cells treated with
FBS, 100 U/ml penicillin, and 100 μg/ml
vehicle; cp < 0.05, dp < 0.01, compared with cells treated with PTH; ep < 0.05, fp < 0.01,
streptomycin. After trypsinization of the concompared with cells treated with Izb.
fluent cells, differentiating osteoblasts were
and osteogenesis in vitro and therapeutic efficacy in animal models
cultured in the presence of 50 μg/ml ascorbic acid for 7 d and used
of osteoporosis.
in the experiments.

MATERIALS AND METHODS

cAMP formation and detection

Human [Nor8,18,Tyr34]PTH(1-34) was purchased from Bachem California (Torrance, CA). Carfilzomib was purchased from LC Laboratories (Woburn, MA), and Izb was obtained from Selleck Chemicals
(Houston, TX). Both drugs were prepared in a 10 mM stock solution
in dimethyl sulfoxide (DMSO) and diluted in plain medium just before use. Antibodies of β-catenin phosphorylation at Ser-675,
phospho-GSK3β (Ser-9), GSK3β, phospho-CREB, and CREB were
obtained from Cell Signaling Technology (Danvers, MA). HA.11 ascites monoclonal antibody (mAb) and HA.11 monoclonal affinity
matrix were purchased from Covance (Berkeley, CA). Actin polyclonal antibody and lamin B1 mAb were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal β-catenin antibody
and Fluo-4 AM were obtained from BD Biosciences (San Jose, CA).
Lentiviral particles of reporter gene CRE-luc were from Qiagen
(Germantown, MD). GeneArt CRISPR Nuclease Vector with orange
fluorescent protein (OFP) reporter kit (A21174), α-MEM, OptiMEM, and Lipofectamine 2000 were purchased from Invitrogen

Saos2 cells were transfected with Glosensor cAMP reporter plasmid
(pGS-22F) in a six-well plate by Lipofectamine 2000 following the
manufacturer’s instruction. After 36 h of transfection, cells were
transferred into a 96-well plate. The confluent cells were then
treated with vehicle or Izb (100 nM) at the indicated time points.
After treatment, cells were incubated with luciferin for 20 min at
room temperature, and then PTH or vehicle was added. Luminescence arising from intracellular cAMP binding to the Glosensor reporter protein was measured in real time at 2-min intervals for
60 min using a plate reader (Synergy-2; Gidon et al., 2014; Carter
et al., 2015). The peak response time occurred by 16 min.
Additional cAMP measurements were performed in primary osteoblasts and Saos2-β-Cat-KO cells and Saos2-β-Cat-Ctr cells. These
cells were treated with vehicle or Izb (100 nM for 3 h). PTH (100 nM
for 15 min)-induced cAMP formation was detected using the cyclic
AMP Direct EIA Kit (Arbor Assays) following the supplier’s instructions. The samples were analyzed by using a cAMP standard curve.
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Cell viability assay
Cell viability was measured as described
previously (Yang et al., 2015). Briefly,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each
well at a final concentration of 500 μg/ml.
The cells were further incubated for 1 h at
37°C in a 5% CO2 atmosphere, and the liquid in the wells was subsequently removed.
DMSO was then added to each well, and
the absorbance was measured at 570 nm.

Knockout of β-catenin gene expression
in Saos2 cells

FIGURE 7: Izb facilitates PTH-induced Wnt/β-catenin signaling. (A) Izb enhances PTH-stimulated
nuclear β-catenin expression. Saos2 cells were treated with Izb (100 nM) for the first 3 h,
followed by an additional 5 h of culture in Izb-free medium in the presence or absence of PTH
(100 nM) for 8 h. Left, nuclear proteins were prepared and β-catenin expression was analyzed by
immunoblotting. Right, quantified nuclear β-catenin expression in four independent experiments
presented as mean ± SE. ap < 0.05, bp < 0.01, compared with cells treated with vehicle;
c
p < 0.05, dp < 0.01, compared with cells treated with PTH; ep < 0.05, fp < 0.01, compared with
cells treated with Izb. (B) Izb promotes PTH-induced TCF reporter activity. Saos2 cells were
seeded into a 12-well plate. After 90% confluence, the cells were transfected with TOPflash or
FOPflash plasmid. At 36 h after transfection, the cells were serum starved for 12 h and then
treated with Izb for the first 3 h, followed by an additional 5 h of culture in Izb-free medium in
the presence or absence of PTH (100 nM), PKA inhibitor H89 (5 µM), or PKC inhibitor Bis I (5 µM)
for 8 h. The β-catenin/TCF activation was measured as described in Materials and Methods.
Data are summarized as mean ± SE of triplicate measurements. n =3. ap < 0.05, bp < 0.01,
compared with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with
PTH; ep < 0.05, fp < 0.01, compared with cells treated with PTH plus Izb.

Constitutive β-catenin expression in Saos2
cells was knocked out using the CRISPR/Cas9
genome-editing technique. Table 1 lists the
double-stranded oligonucleotides encoding
a CRISPR targeting RNA (crRNA) of β-catenin
that allows sequence-specific targeting of the
Cas9 nuclease. The double-stranded oligonucleotides were cloned into linearized
GeneArt CRISPR nuclease vectors with an
OFP reporter following the manufacturer’s
protocol. Saos2 cells were seeded into a sixwell plate. After cells reached 90% confluence, CRISPR plasmid or control plasmid was
transfected into the cells using Lipofectamine
2000 following the manufacturer’s protocol.
Two days after the transfection, the cells were
counted and seeded into a 96-well plate with
one cell per well by a serial dilution. OFP reporter was applied to monitor transfection
efficiency in cells for fluorescence-based
tracking using an Evos machine (Invitrogen).
After ∼3 wk, Western blotting was used to
screen β-catenin expression in cells. Zero expression of β-catenin was identified in two
single colonies when the cells were transfected with CRISPR construct, whereas βcatenin expression was not changed in cells
transfected with the control plasmid.

Intracellular calcium assay

Cell fractionation

Saos2 cells were seeded into poly-d-lysine–coated 96-well plates
and grown to confluence. The cells were then treated with vehicle or
Izb (100 nM) for 3 h. After treatment, the cells were loaded with 2
μM Fluo-4 AM according to the manufacturer’s protocol. PTH or
vehicle was added by an automated pipetting system in triplicate,
and the 525-nm signals were generated by excitation at 485 nm
with a Flex Station II (Molecular Devices, Sunnyvale, CA) as previously reported (Deshpande et al., 2014). Maximal Ca2+ response
was determined by stimulating the cells with 1 µM ionomycin. The
net peak Ca2+ response was calculated using the equation (maximum agonist-induced fluorescence units) − (basal fluorescence
units).

Membrane and nuclear proteins were prepared by fractionating cell
lysates using differential centrifugation at 4°C as described previously (Wang et al., 2008; Hu et al., 2013). Briefly, cells treated with
Izb, PTH, or vehicle were harvested in hypotonic buffer (10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 1 mM
MgCl2, 0.5 mM CaCl2, 1 mM EDTA) supplemented with protease
inhibitor cocktail set I and then homogenized by 30 strokes of a
Dounce homogenizer. After removal of the nuclear pellet, lysates
were separated into cytosolic and membrane fractions by ultracentrifugation (100,000 × g) for 60 min. The membrane proteins were
used for the interaction of β-catenin with the PTHR, and the nuclear
proteins were subjected to immunoblot analysis for β-catenin
expression.

CRE-luc assay
Saos2 cells were infected with lentiviral particles of CRE reporter.
After 48 h, the cells were serum starved overnight and then treated
with Izb, PTH, or vehicle at the indicated time points. The CRE-luc
activity was detected as previously described (Yan et al., 2011).
1800 | Y. Yang et al.

Immunoprecipitation and immunoblot analysis
The plasma membrane proteins were solubilized in immunoprecipitation assay buffer (1% Nonidet P-40, 0.5% Na deoxycholate, 0.1%
SDS, 50 mM Tris, pH 7.4, and 150 mM NaCl) supplemented with
Molecular Biology of the Cell

GST–E-cadherin pull-down assay
The GST–E-cadherin binding assay was performed as described
(Qiang et al., 2009). The β-catenin–binding site of E-cadherin was
cloned as a GST-fusion protein, and complexes were purified using
GST beads. GST–E-cadherin was used to precipitate uncomplexed
β-catenin from 500 µg of cell lysates. The free β-catenin fraction
detected by immunoblotting represents active forms of β-catenin
(Qiang et al., 2009).

Fluorescence staining

FIGURE 8: Model of Izb regulation of PTHR signaling cascade in
bone. Both PTH and Izb are able to induce β-catenin (β-Cat)/TCF
signaling. Izb stabilizes β-Cat by inhibiting its proteasome
degradation. β-Cat–mediated PTHR signaling switch is blocked by Izb
due to its promoting of β-Cat translocation, thereby dissociating
β-Cat from the PTHR. Izb facilitates PTH stimulation of CREB
phosphorylation, β-Cat (Ser-675) phosphorylation, GSK3β (Ser-9)
phosphorylation, and TCF/Lef activity through a cAMP/PKA signaling
pathway. Collectively these findings suggest that the combination of
PTH and Izb favors the anabolic PTH action in bone.

protease inhibitor cocktail set I. HA beads were added to equal
amounts of soluble membrane proteins in each group. Immunoprecipitated proteins, nuclear proteins, or total lysates (Wang et al.,
2008; Hu et al., 2013) were analyzed by SDS–polyacrylamide gels
and transferred to Immobilon-P membranes (Millipore) using the
semidry method (Bio-Rad). Membranes were blocked with 3% bovine serum albumin in Tris-buffered saline/Tween 20 buffer at room
temperature for 1 h and incubated with different antibodies overnight at 4°C. The membranes were then washed and incubated with
IRDye 800CW goat anti-rabbit immunoglobulin G (IgG) or IRDye
680RD goat anti-mouse IgG at room temperature for 1 h. Band intensity was quantified using the LI-COR Odyssey system (Yang and
Wang, 2015).

Saos2 cells were grown on glass coverslips and then transfected
with GFP-PTHR. After 40 h, the cells were incubated with vehicle or
Izb (100 nM) for 3 h, followed by an additional 5 h of culture in Izbfree medium. The cells were rinsed in phosphate-buffered saline
(PBS), fixed on 4% paraformaldehyde for 10 min, and then permeabilized with 0.2% Triton X-100 for 15 min at room temperature.
Blocking was performed by incubating the cells for 1 h at room temperature in 10% goat serum in PBS. Anti–β-catenin mouse mAb diluted (1:250) in blocking buffer was applied to the specimens for 1 h
at room temperature. Alexa Fluor 546–tagged goat anti-mouse secondary antibody diluted 1:1000 was applied under the same conditions as the primary antibody. Nucleus staining was performed with
DRAQ5. Coverslips were mounted for confocal microscopy (Wang
et al., 2008).

TOPflash/FOPflash activity assay
Saos2 cells or MC4 cells were transfected with TOPflash or FOPflash
in a 12-well plate by using Lipofectamine 2000 according to the
manufacturer’s protocol. After 36 h of transfection, cells were serum
starved for 12 h and then treated with the indicated reagents. Eight
hours after treatment, cells were lysed with reporter lysis buffer (Promega). The cell lysates were then drawn four times through a
21-gauge needle attached to a 1-ml syringe. The supernatants were
transferred to a 96-well plate. The luminescence of each well was
recorded after addition of BioGlo Luciferase substrate (Promega).
The ratio of TOP/FOP signal was calculated and normalized to control conditions.

Statistical analysis
The data are presented as mean ± SE of triplicate measurements. In
the figures, n indicates the number of independent experiments.
Statistical analysis between control and treated groups was performed using Student’s t test. Multiple comparisons in one or two
types of cells were evaluated by one-way or two-way analysis of
variance followed by Bonferroni’s posttest (Prism; GraphPad). p <
0.05 was considered sufficient to reject the null hypothesis.
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